Corp. (NASDAQ: DYAX) announced today that executive management will
participate in two upcoming conferences.
Gustav Christensen, President and Chief Executive Officer of Dyax, will
present on Wednesday, November 14 at 11:20 AM (GMT), at the Jefferies
2012 Global Healthcare Conference, being held November 14-15, 2012 in
Mr. Christensen will also present at Piper Jaffray’s 24th
Annual Healthcare Conference, on Tuesday November 27 at 4:30 PM (ET).
The conference is being held November 27-28, at The New York Palace
Hotel in New York City.
At both events, Mr. Christensen will provide a corporate update
regarding the Company’s key value drivers – KALBITOR®
(ecallantide) and the angioedema portfolio, as well as the Licensing and
Funded Research Program (LFRP).
Both presentations will be webcast live and may be accessed by visiting
the Investor Relations section of the company website at www.dyax.com.
The webcasts will also be available on the Dyax website for a limited
period of time following the conferences.
Dyax is a fully integrated biopharmaceutical company focused on the
discovery, development and commercialization of novel biotherapeutics
for unmet medical needs. The Company’s key value drivers are the KALBITOR®
(ecallantide) business and the angioedema portfolio, as well as the
Licensing and Funded Research Program (LFRP).
Dyax developed KALBITOR on its own and, since February 2010, the Company
has been selling it in the United States for the treatment of acute
attacks of hereditary angioedema (HAE) in patients 16 years of age and
older. Outside the United States, the Company has established
partnerships to obtain regulatory approval for and commercialization of
KALBITOR in certain markets and is evaluating opportunities in others.
The Company is currently developing products to expand its angioedema
portfolio, including a diagnostic strategy to identify plasma kallikrein
(bradykinin) mediated (PKM) angioedema and a therapeutic candidate,
DX-2930, for the prophylactic treatment of PKM angioedema.
KALBITOR and DX-2930 were identified using Dyax’s patented phage display
technology, which rapidly selects compounds that bind with high affinity
and specificity to therapeutic targets. Dyax leverages this technology
broadly through the LFRP. This program has provided the Company a
portfolio of product candidates being developed by its licensees, which
currently includes 11 royalty and/or milestone bearing product
candidates in various stages of clinical development, including three in
Phase 3 trials.
Dyax is headquartered in Burlington, Massachusetts. For additional
information about Dyax, please visit www.dyax.com.